2 Results for "

late cell-cycle progression

" in MedChemExpress (MCE) Product Catalog:
Products (2)

2 Results for "late cell-cycle progression" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-111380
CAS No.: 1425945-60-3
Purity:  98.16%
Target:  

DYRK

Research Areas:  

Neurological Disease

EHT 1610 is a potent inhibitor of DYRK, with IC50s of 0.36 nM (DYRK1A), 0.59 nM (DYRK1B), respectively. EHT 1610 exhibits antileukemia effect, regulates cell cycle and induces cell apoptosis - .
loading...
    loading...
Cat. No.: HY-183480
CAS No.: 80841-47-0
Synonyms: CI-921; NSC 343499
Target:  

Topoisomerase

Research Areas:  

Cancer

Asulacrine (CI-921) is an orally active DNA intercalating topoisomerase II inhibitor. Asulacrine binds to DNA via intercalation, with its acridine chromophore intercalated between base pairs and substituents located in the major/minor grooves, which stabilizes DNA against acid denaturation. Asulacrine acts as a cell cycle inhibitor, disruptor, and arrest inducer, slowing cell progression in late S/G2 phase, causing G2 phase arrest and inducing unbalanced growth. Asulacrine inhibits cell growth, clonogenicity, and colony formation, and leads to histological destruction of tumor cells. Compared to cells in exponential growth phase, Asulacrine exhibits lower toxicity to quiescent cells; its activity depends on cationic properties, and it has better water solubility and metabolic stability. Asulacrine can be used in research related to leukemia, lung cancer, colon cancer, breast cancer, melanoma, adriamycin-resistant mammary adenocarcinoma, and mouse solid tumors .
loading...
    loading...